EXPERTS AT BIO CONFERENCE TO ADDRESS NOVEL DRUGS AND APPROACHES IN CANCER, NEUROLOGY AND OTHER DISEASES
WASHINGTON, D.C. (September 28, 2004) -- Industry and clinical experts will meet to address the development of novel drugs for the treatment of cancer, neurological and other diseases, as well as the latest approaches to expediting drug discovery, disease target validation and clinical development at the Biotechnology Industry Organization’s first annual BIO Emerging Company Investor Forum, October 13-15, San Francisco.
With more than 12 scientific and clinical workshops, the forum was developed to offer innovative life sciences companies a platform to educate investors and industry on basic and translational research topics that will shape the industry for decades to come. Workshops include such topics as:
• Future of Obesity Therapy: Diet? Drugs? Devices?
Wednesday, October 13, 4-5 p.m.
Moderated by William Greene, MD, Principal at MPM Capital, LP
Leading practitioners and clinical experts in the field will discuss the latest clinical thinking on multi-approach treatments, including drugs, diets, and devices, as well as drugs with novel mechanisms of actions and targets and their role in obesity treatment regimens.
• Cancer Trial Endpoints: The Bar Keeps Moving
Thursday, October 14, 9:30 - 10:30 a.m.
Moderated by Joel Sendek, Director and Senior Biotechnology Analyst at Lazard
FDA representatives, drug development executives and clinical trial designers and clinicians will discuss the impact of an evolving regulatory landscape on the cancer drug development and approval process.
• Beyond Crystal Balls: Using Preclinical Testing Technologies to Enhance the Drug Development Cycle
Friday, October 15, 8:30 - 9:30 a.m.
Moderated by Donald Black, MD, VP of Global Strategic Regulatory Development at Merck Co. Inc.
A distinguished group of industry and academic experts will discuss how advances in novel technologies and approaches to toxicology, formulation, ADME and pharmacology in preclinical testing can impact clinical outcomes and successful drug development.
“We anticipate broad interest in hearing industry experts, academicians and clinical investigators discuss how to prioritize and expedite drug development programs, evaluate newly characterized disease targets and access the value of innovative technologies that drive drug discovery success. The program will touch upon the most competitive therapeutic product development areas in biotech and specialty pharma including oncology, neurology, obesity, autoimmune disorders, as well as important technology applications in personalized medicine and genetic expression and mapping in the industry,” said Morrie Ruffin, vice president, business development and emerging companies, BIO.
To register and for more information on these workshops, and the expanded program including business-focused roundtables, plenary sessions and leading clinical and industry keynote speakers, please visit www.bio.org/events/. Registration is complimentary for credentialed news media and investors.
About the BIO Emerging Company Investor Forum
The Biotechnology Industry Organization (BIO) and five leading investment banks have joined together to host the BIO Emerging Company Investor Forum. Positioned as the foremost event of its kind, the forum will address an unmet need, identified by industry executives and the investment community, for a conference exclusively focused on the most promising public and late-stage private companies in the biotechnology industry. This event is hosted by Lazard and Banc of America Securities and co-hosted by CIBC World Markets, Pacific Growth Equities and Citigroup.
About BIOBIO represents more than 1,000 biotechnology companies, academic institutions, state biotechnology centers and related organizations in all 50 U.S. states and 33 other nations. BIO members are involved in the research and development of health-care, agricultural, industrial and environmental biotechnology products.
###